Detalhe da pesquisa
1.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-31877211
2.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Haematologica
; 107(10): 2356-2364, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35385922
3.
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Cancer
; 124(10): 2228-2237, 2018 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29499087
4.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Am J Hematol
; 92(1): 82-87, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27770583
5.
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
Haematologica
; 101(10): 1200-1207, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27470600
6.
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
Haematologica
; 100(9): 1146-50, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26113419
7.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Cancer
; 120(7): 1002-9, 2014 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24382642
8.
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
Qual Life Res
; 23(3): 825-36, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24026634
9.
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Cancer
; 118(21): 5265-9, 2012 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22517301
10.
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
Target Oncol
; 16(6): 823-838, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34661826
11.
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Blood Adv
; 3(24): 4280-4290, 2019 12 23.
Artigo
Inglês
| MEDLINE | ID: mdl-31869412
12.
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.
Oncotarget
; 8(20): 32608-32617, 2017 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-28427233
13.
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Oncotarget
; 7(16): 21982-90, 2016 Apr 19.
Artigo
Inglês
| MEDLINE | ID: mdl-26980736
14.
Cryptic translocation of PML/RARA on 17q. A rare event in acute promyelocytic leukemia.
Cancer Genet Cytogenet
; 138(2): 169-73, 2002 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12505266
15.
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Haematologica
; 87(8): 816-21, 2002 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-12161357